BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 29914543)

  • 1. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.
    Onishi T; Matsumoto Y; Hattori M; Obayashi Y; Nakamura K; Yano T; Horiguchi T; Iwashita H
    Neurosci Res; 2014 Mar; 80():76-85. PubMed ID: 24406748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.
    Chalermpalanupap T; Schroeder JP; Rorabaugh JM; Liles LC; Lah JJ; Levey AI; Weinshenker D
    J Neurosci; 2018 Jan; 38(1):74-92. PubMed ID: 29133432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
    Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
    J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease.
    Sun XY; Li LJ; Dong QX; Zhu J; Huang YR; Hou SJ; Yu XL; Liu RT
    J Neuroinflammation; 2021 Jun; 18(1):131. PubMed ID: 34116706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease.
    Wang SW; Liu DQ; Zhang LX; Ji M; Zhang YX; Dong QX; Liu SY; Xie XX; Liu RT
    Alzheimers Res Ther; 2017 Jun; 9(1):41. PubMed ID: 28592267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
    Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
    Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.
    Gonzalez-Castro R; Acero Galindo G; García Salcedo Y; Uribe Campero L; Vazquez Perez V; Carrillo-Tripp M; Gevorkian G; Gomez Lim MA
    Inflammopharmacology; 2018 Jun; 26(3):817-827. PubMed ID: 29094307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease.
    Sun Y; Guo Y; Feng X; Jia M; Ai N; Dong Y; Zheng Y; Fu L; Yu B; Zhang H; Wu J; Yu X; Wu H; Kong W
    J Neuroinflammation; 2020 Feb; 17(1):72. PubMed ID: 32093751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice.
    Hu Y; Lai J; Wan B; Liu X; Zhang Y; Zhang J; Sun D; Ruan G; Liu E; Liu GP; Chen C; Wang DW
    Neurotoxicology; 2016 Mar; 53():290-300. PubMed ID: 26945731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia.
    Przybyla M; Stevens CH; van der Hoven J; Harasta A; Bi M; Ittner A; van Hummel A; Hodges JR; Piguet O; Karl T; Kassiou M; Housley GD; Ke YD; Ittner LM; van Eersel J
    Neurosci Lett; 2016 Sep; 631():24-29. PubMed ID: 27521751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory deficits correlate with tau and spine pathology in P301S MAPT transgenic mice.
    Xu H; Rösler TW; Carlsson T; de Andrade A; Bruch J; Höllerhage M; Oertel WH; Höglinger GU
    Neuropathol Appl Neurobiol; 2014 Dec; 40(7):833-43. PubMed ID: 24865638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.
    Troquier L; Caillierez R; Burnouf S; Fernandez-Gomez FJ; Grosjean ME; Zommer N; Sergeant N; Schraen-Maschke S; Blum D; Buee L
    Curr Alzheimer Res; 2012 May; 9(4):397-405. PubMed ID: 22272619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
    Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
    PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
    Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT
    Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.
    Davtyan H; Chen WW; Zagorski K; Davis J; Petrushina I; Kazarian K; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
    Vaccine; 2017 Apr; 35(16):2015-2024. PubMed ID: 28320590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.